Abstract: Microfluidic devices and methods that utilize ion concentration polarization within water-in-oil nanoliter scale droplets for concentration enrichment, separation, and substitution of charges species are disclosed. Such devices and methods can be used for separation of multiple species by mobility of each species and for the alteration and manipulation of the droplet composition by ion exchange.

Abstract: High-throughput microfluidic devices comprising one or more fluidic microchannels each with at least one flow-through 3D structure comprising a 3D electrode, or alternatively a 3D permselective structure, and optional secondary bead bed(s) are disclosed. Such devices can be used for counter-flow focusing of charged species via ion concentration polarization and in situ quantification of electrokinetically enriched charged species from an ionically conductive solution by both optical and electrical detection.

Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.

Abstract: According to one aspect of the present disclosure, a method and technique for hybrid virtual machine configuration management is disclosed. The method includes assigning to a first set of virtual resources associated with a virtual machine a first priority and assigning to a second set of virtual resources associated with the virtual machine a second priority lower than the first priority. An operating system of the virtual machine is provided with the first and second priorities assigned to the respective first and second sets of virtual resources. The operating system dispatches to process a workload the virtual resources from the first set before dispatching the virtual resources from the second set.

Abstract: A portable device for removal of metabolic waste from the blood of patient having kidney disease or in need of hemodialysis is provided. Methods of hemodialysis employing the portable device beneficially obtain a dialysate by electrokinetic means from excess fluid in the peripheral blood of the patient in need thereof. The methods employ a branched microfluidic channel for the use of ion concentration polarization to separate charged from neutral species in blood to obtain the dialysate for undergoing hemodialysis. Beneficially the methods and device are resistant to biofouling, remove the need for a dialysate and/or dialysate reservoir, and provide a disposable, wearable device.

Abstract: Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.

Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof: The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Abstract: A microfluidic device comprising one or more fluidic microchannels and one or more arrays of wireless bipolar electrodes is disclosed. The disclosed microfluidic device can be used to separate cells, especially rare cells, from its biological matrix. The disclosed device can isolate cells in a high-throughput fashion and without any modification or labelling to the cells. Cells isolated using the disclosed devices does not lose their vitality.

Abstract: In a load balancing environment, a method, system, and computer program product may balance workloads by deploying one or more applications, defining a priority for a first application of the one or more applications, assigning a set of dynamic resources to the first application, configuring a set of burst reserves for the first application, configuring a schedule for the priority for the first application, configuring an elastic load balancer to manage the workload of the first application according to the priority and scheduling using the set of dynamic resources and burst reserves, and executing the one or more applications.

Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.

Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.

Abstract: In a load balancing environment, a method, system, and computer program product may balance workloads by deploying one or more applications, defining a priority for a first application of the one or more applications, assigning a set of dynamic resources to the first application, configuring a set of burst reserves for the first application, configuring a schedule for the priority for the first application, configuring an elastic load balancer to manage the workload of the first application according to the priority and scheduling using the set of dynamic resources and burst reserves, and executing the one or more applications.

Abstract: A microfluidic device comprising one or more fluidic microchannels and one or more arrays of cell assay units is disclosed. Each cell assay unit in turn comprises at one bipolar electrode, micropocket, reaction chamber, and leak channel. In some embodiments, the cell assay unit further comprises two or more split BPEs inside the reaction chamber. The disclosed microfluidic device can be used to separate cells, especially rare cells, from its biological matrix and then analyze the isolated cell inside the reaction chamber. The disclosed device can isolate and analyze cells in a high-throughput fashion and without any modification or labelling to the cells. Cells isolated using the disclosed devices does not lose their vitality.

Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.